Showing results (51-60 of 62) with videos related to

Sort By:
Pageof 7
Hepatology (Baltimore, Md.)|March 1, 2002
Time-dependent Cox regression model is superior in prediction of prognosis in primary sclerosing cholangitisKirsten Muri Boberg, Giuseppe Rocca, Thore Egeland, et al.
The American Journal of Surgical Pathology|October 26, 2006
Lobular intraepithelial neoplasia [lobular carcinoma in situ] with comedo-type necrosis: A clinicopathologic study of 18 casesOluwole Fadare, Farnaz Dadmanesh, Isabel Alvarado-Cabrero, et al.
Toxicology Letters|March 1, 2024
Non-invasive methods of monitoring Fe<sub>3</sub>O<sub>4</sub> magnetic nanoparticle toxicity in human liver HepaRG cells using impedance biosensing and Coherent anti-Stokes Raman spectroscopic (CARS) microscopyJoel Kuhn, Alison McDonald, Cyril Mongoin, et al.
Journal of Neuromuscular Diseases|June 29, 2024
A Systematic Literature Review of the Natural History of Respiratory, Swallowing, Feeding, and Speech Functions in Spinal Muscular Atrophy (SMA)Yasmina Martí, Valerie Aponte Ribero, Sarah Batson, et al.
Bioorganic & Medicinal Chemistry Letters|April 17, 2007
Naphthyl piperazines with dual activity as 5-HT1D antagonists and 5-HT reuptake inhibitorsAna B Bueno, Jeremy Gilmore, John Boot, et al.
Elife|September 19, 2025
Blue-shifted ancyromonad channelrhodopsins for multiplex optogeneticsElena G Govorunova, Oleg A Sineshchekov, Hai Li, et al.
Biorxiv : the Preprint Server for Biology|March 10, 2025
Blue-shifted ancyromonad channelrhodopsins for multiplex optogeneticsElena G Govorunova, Oleg A Sineshchekov, Hai Li, et al.
BJU International|September 26, 2024
Real-world outcomes for high-risk non-muscle-invasive bladder cancer: screened patients for the BRAVO trialSamantha Conroy, Ibrahim Jubber, Aidan P Noon, et al.
Bioorganic & Medicinal Chemistry Letters|April 28, 2004
SAR development of a selective 5-HT1D antagonist/serotonin reuptake inhibitor lead using rapid parallel synthesisGraham H Timms, John R Boot, Richard J Broadmore, et al.
Heart, Lung & Circulation|December 12, 2018
Risk Calculator to Predict 30-Day Readmission After Coronary Artery Bypass: A Strategic Decision Support ToolSalil V Deo, Sajjad Raza, Salah E Altarabsheh, et al.
Pageof 7